Ongoing Pelareorep Clinical Studies
| Programs | Combination | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Milestone |
|---|---|---|---|---|---|---|---|
Breast Cancer |
|||||||
|
BRACELET-1
|
|
mBC (HR+/HER2-) |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Fully Enrolled Q4 2021/Q1 2022
|
|
AWARE-1
|
|
Early stage BC |
Window of Opportunity Study
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Final Biomarker Data H2 2021
|
|
IRENE
|
Retifanlimab* | TNBC |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Phase 2 Safety Data Q4 2021
|
Gastro-Intestinal Cancer |
|||||||
|
GOBLET
|
|
Multiple GI Cancers |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
FPI Achieved H2 2021
|
|
NU 18I01
|
|
Pancreatic Cancer |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Phase 2 Data H1 2021
|
Multiple Myeloma |
|||||||
|
NCI-9603
|
|
R/R Multiple Myeloma |
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Interim Data Achieved Q2 2020
|
|
WINSHIP 4398-18
|
|
R/R Multiple Myeloma |
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Phase 1 Safety Data H1 2022
|
*Anti-PD-1 checkpoint inhibitor in development by Incyte (also known as INCMGA00012)